## OF E 44.00 BY THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of .:

Joseph ITSKOVITZ-ELDOR et al

Serial No.:

10/536,734

Filed:

May 27, 2005

For:

CULTURED HUMAN PANCREATIC

ISLETS, AND USES THEREOF

Examiner:

Taevoon Kim

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Group Art Unit:

§

1651

Attorney Docket:

29601

## ELECTION

Sir:

This is in response to the United States Patent and Trademark Restriction Office Action mailed September 27, 2007, which response is being made on or before November 27, 2007, and for which a one month's extension of time fee is due and enclosed herewith.

The Examiner has required further selection of a single species from each of the groups as indicated in the Office Action.

For the type of third set of culturing medium, Applicants hereby elect "a culture medium including glucose at a concentration of 15 millimolar or less".

For the type of fourth set of culturing medium, Applicants hereby elect "a substantially serum free culture medium".

For the type of islet cell phenotype, Applicants hereby elect "a beta cell phenotype".

For the type of drug, Applicants hereby elect "tolbutamide".

For the type of human embryonic stem cell, Applicants hereby elect "H13 cells".

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Group.

Respectfully submitted,
Marlon D. Mogruha

Martin D. Moynihan Registration No. 40,338

Date: October 30, 2007